About vyne therapeutics inc - VYNE
VYNE Therapeutics, Inc. engages in the manufacture of pharmaceutical products. It develops and commercializes solutions using its proprietary Molecule Stabilizing Technology. Its commercial products include AMZEEQ and ZILXI. The company was founded in October 2011 and is headquartered in Stewartsville, NJ.
VYNE At a Glance
VYNE Therapeutics, Inc.
P.O. Box 125
Stewartsville, New Jersey 08886
| Phone | 1-800-755-7936 | Revenue | 570.00K | |
| Industry | Pharmaceuticals: Major | Net Income | -26,483,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 13.772% | |
| Fiscal Year-end | 12 / 2026 | Employees | 10 | |
| View SEC Filings |
VYNE Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 43.526 |
| Price to Book Ratio | 0.696 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.141 |
| Enterprise Value to Sales | -7.365 |
| Total Debt to Enterprise Value | N/A |
VYNE Efficiency
| Revenue/Employee | 57,000.00 |
| Income Per Employee | -2,648,300.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.012 |
VYNE Liquidity
| Current Ratio | 12.53 |
| Quick Ratio | 12.53 |
| Cash Ratio | 12.112 |
VYNE Profitability
| Gross Margin | 95.965 |
| Operating Margin | -5,219.123 |
| Pretax Margin | -4,689.825 |
| Net Margin | -4,646.14 |
| Return on Assets | -55.089 |
| Return on Equity | -66.965 |
| Return on Total Capital | -96.294 |
| Return on Invested Capital | -66.965 |
VYNE Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |